Carly Baehr

428 total citations
22 papers, 291 citations indexed

About

Carly Baehr is a scholar working on Molecular Biology, Pharmacology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Carly Baehr has authored 22 papers receiving a total of 291 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Pharmacology and 6 papers in Cellular and Molecular Neuroscience. Recurrent topics in Carly Baehr's work include Monoclonal and Polyclonal Antibodies Research (6 papers), Forensic Toxicology and Drug Analysis (6 papers) and Opioid Use Disorder Treatment (5 papers). Carly Baehr is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), Forensic Toxicology and Drug Analysis (6 papers) and Opioid Use Disorder Treatment (5 papers). Carly Baehr collaborates with scholars based in United States, Italy and Germany. Carly Baehr's co-authors include Marco Pravetoni, Christine Robinson, Saadyah Averick, Catherine J. Huntoon, Larry M. Karnitz, David P. AuCoin, Federico Baruffaldi, Scott P. Runyon, Xiaoxiao Wang and Jill M. Wagner and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Immunology and Analytical Chemistry.

In The Last Decade

Carly Baehr

20 papers receiving 291 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carly Baehr United States 11 150 102 68 56 52 22 291
Megan Laudenbach United States 10 126 0.8× 154 1.5× 101 1.5× 114 2.0× 80 1.5× 12 341
Dan Fu China 16 138 0.9× 46 0.5× 17 0.3× 63 1.1× 15 0.3× 67 650
Charlotte E. Farquhar United States 12 144 1.0× 145 1.4× 216 3.2× 3 0.1× 94 1.8× 17 392
Marianne Mikkelsen Denmark 10 113 0.8× 142 1.4× 45 0.7× 6 0.1× 9 0.2× 17 607
Ronald W. McLawhon United States 14 181 1.2× 102 1.0× 19 0.3× 8 0.1× 8 0.2× 19 456
Valeria Feinshtein Israel 12 113 0.8× 25 0.2× 98 1.4× 35 0.6× 5 0.1× 21 329
Elise Wouters Belgium 10 138 0.9× 199 2.0× 141 2.1× 5 0.1× 106 2.0× 15 331
Nina Lindblom Sweden 10 204 1.4× 89 0.9× 43 0.6× 20 0.4× 38 0.7× 11 355
Aurore Devos France 7 153 1.0× 38 0.4× 28 0.4× 16 0.3× 14 0.3× 14 267
Michael J. Capper United Kingdom 5 96 0.6× 26 0.3× 20 0.3× 39 0.7× 14 0.3× 8 242

Countries citing papers authored by Carly Baehr

Since Specialization
Citations

This map shows the geographic impact of Carly Baehr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carly Baehr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carly Baehr more than expected).

Fields of papers citing papers by Carly Baehr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carly Baehr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carly Baehr. The network helps show where Carly Baehr may publish in the future.

Co-authorship network of co-authors of Carly Baehr

This figure shows the co-authorship network connecting the top 25 collaborators of Carly Baehr. A scholar is included among the top collaborators of Carly Baehr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carly Baehr. Carly Baehr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gay, Elaine A., et al.. (2025). In vitro biophysical and pharmacological profiling predicts in vivo efficacy of anti-carfentanil monoclonal antibodies in mice. Biochemical and Biophysical Research Communications. 770. 151995–151995. 1 indexed citations
2.
Baehr, Carly, et al.. (2025). A humanized monoclonal antibody attenuates carfentanil self-administration in nonhuman primates. Drug and Alcohol Dependence Reports. 16. 100365–100365.
3.
4.
Lake, Eric W., et al.. (2024). Identification and biophysical characterization of a novel domain-swapped camelid antibody specific for fentanyl. Journal of Biological Chemistry. 300(8). 107502–107502. 1 indexed citations
5.
Urban, Katharina, Sandra Ruf, Marco Pravetoni, et al.. (2024). The fentanyl-specific antibody FenAb024 can shield against carfentanil effects. Toxicology Letters. 396. 1–10. 4 indexed citations
6.
Baehr, Carly, et al.. (2024). Monoclonal Antibodies Engineered with Fc Region Mutations to Extend Protection against Fentanyl Toxicity. The Journal of Immunology. 213(5). 663–668. 4 indexed citations
7.
Baehr, Carly, et al.. (2024). Structure-Based Engineering of Monoclonal Antibodies for Improved Binding to Counteract the Effects of Fentanyl and Carfentanil. ACS Omega. 9(41). 42506–42519. 2 indexed citations
8.
Baehr, Carly, et al.. (2023). IL-4 Predicts the Efficacy of a Candidate Antioxycodone Vaccine and Alters Vaccine-Specific Antibody-Secreting Cell Proliferation in Mice. The Journal of Immunology. 210(9). 1272–1280. 4 indexed citations
9.
Baehr, Carly, et al.. (2023). Anti-Fentanyl Monoclonal Antibodies: In Vitro Characterization and In Vivo Efficacy in Reversing Apnea in Pigs. Journal of Pharmacology and Experimental Therapeutics. 385. 513–513.
10.
Baehr, Carly, et al.. (2022). Advancing humanized monoclonal antibody for counteracting fentanyl toxicity towards clinical development. Human Vaccines & Immunotherapeutics. 18(6). 2122507–2122507. 18 indexed citations
11.
Baehr, Carly, Connor Weidle, Peter B. Rupert, et al.. (2022). Structures of drug-specific monoclonal antibodies bound to opioids and nicotine reveal a common mode of binding. Structure. 31(1). 20–32.e5. 12 indexed citations
12.
Baehr, Carly, Christine Robinson, Andrew J. Kassick, et al.. (2022). Preclinical Efficacy and Selectivity of Vaccines Targeting Fentanyl, Alfentanil, Sufentanil, and Acetylfentanyl in Rats. ACS Omega. 7(19). 16584–16592. 18 indexed citations
13.
Baehr, Carly, et al.. (2022). Pharmacological Profiling of Antifentanyl Monoclonal Antibodies in Combination with Naloxone in Pre- and Postexposure Models of Fentanyl Toxicity. Journal of Pharmacology and Experimental Therapeutics. 381(2). 129–136. 17 indexed citations
14.
Ross, Jennifer A., et al.. (2021). A Membrane-Modulated Centrifugal Microdevice for Enzyme-Linked Immunosorbent Assay-Based Detection of Illicit and Misused Drugs. Analytical Chemistry. 93(48). 16213–16221. 8 indexed citations
15.
Robinson, Christine, Carly Baehr, Saadyah Averick, et al.. (2020). Therapeutic and Prophylactic Vaccines to Counteract Fentanyl Use Disorders and Toxicity. Journal of Medicinal Chemistry. 63(23). 14647–14667. 37 indexed citations
16.
Baehr, Carly, et al.. (2020). Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats. Journal of Pharmacology and Experimental Therapeutics. 375(3). 469–477. 39 indexed citations
17.
Laudenbach, Megan, Federico Baruffaldi, Christine Robinson, et al.. (2018). Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose. Scientific Reports. 8(1). 5508–5508. 32 indexed citations
18.
Baehr, Carly & Marco Pravetoni. (2018). Vaccines to treat opioid use disorders and to reduce opioid overdoses. Neuropsychopharmacology. 44(1). 217–218. 15 indexed citations
19.
20.
Huehls, Amelia M., Catherine J. Huntoon, Poorval Joshi, et al.. (2015). Genomically Incorporated 5-Fluorouracil that Escapes UNG-Initiated Base Excision Repair Blocks DNA Replication and Activates Homologous Recombination. Molecular Pharmacology. 89(1). 53–62. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Megan Laudenbach Breakdown of academic impact, for papers by Dan Fu Breakdown of academic impact, for papers by Charlotte E. Farquhar Breakdown of academic impact, for papers by Marianne Mikkelsen Breakdown of academic impact, for papers by Ronald W. McLawhon Breakdown of academic impact, for papers by Valeria Feinshtein Breakdown of academic impact, for papers by Elise Wouters Breakdown of academic impact, for papers by Nina Lindblom Breakdown of academic impact, for papers by Aurore Devos Breakdown of academic impact, for papers by Michael J. Capper
Rankless by CCL
2026